Macrophage migration inhibitory factor expression and MIF gene - 173 G/C polymorphism in nonalcoholic fatty liver disease

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 2, 2010, Pages 192-198

  Akyildiz, Murat ^a   Gunsar, Fulya ^a   Nart, Deniz ^a   Sahin, Osman ^a   Yilmaz, Funda ^a   Akay, Sinan ^a   Ersoz, Galip ^a   Karasu, Zeki ^a   Ilter, Tankut ^a   Batur, Yucel ^a   Berdeli, Afig ^a   Akarca, Ulus ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Gene polymorphism; Liver; Macrophage migration inhibitory factor; Nonalcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; MACROPHAGE MIGRATION INHIBITION FACTOR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RESTRICTION FRAGMENT; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STEATOSIS;

ADULT; BIOPSY; CASE-CONTROL STUDIES; FATTY LIVER; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; INTRAMOLECULAR OXIDOREDUCTASES; LIVER; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; SEVERITY OF ILLNESS INDEX; UP-REGULATION;

EID: 75749152670     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328331a596     Document Type: Article

References (38)

1. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003; 3:791-800. (Pubitemid 37328657)
2. Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M, et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A 1996; 93:7849-7854. (Pubitemid 26277127)
3. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995; 377:68-71.
4. Donn RP, Ray DW. Macrophage migration inhibitory factor: molecular, cellular and genetic aspects of a key neuroendocrine molecule. J Endocrinol 2004; 182:1-9.
5. Shimizu T, Abe R, Nakamura H, Ohkawara A, Suzuki M, Nishihira J. High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun 1999; 264:751-758.
6. Baugh JA, Donnelly SC. Macrophage migration inhibitory factor: a neuroendocrine modulator of chronic inflammation. J Endocrinol 2003; 179:15-23.
7. Lolis E. Glucocorticoid counter regulation: macrophage migration inhibitory factor as a target for drug discovery. Curr Opin Pharmacol 2001; 1: 662-668.
8. Makita H, Nishimura M, Miyamoto K, Nakano T, Tanino Y, Hirokawa J, et al. Effect of anti-macrophage migration inhibitory factor antibody on lipopolysaccharide-induced pulmonary neutrophil accumulation. Am J Respir Crit Care Med 1998; 158:573-579.
9. Matsui Y, Okamoto H, Jia N, Akino M, Uede T, Kitabake A, Nishihira J. Blockade of macrophage migration inhibitory factor ameliorates experimental autoimmune myocarditis. J Molecular and Cellular Cardiology 2004; 37:557-566.
10. Donn R, Alourfi Z, De Benedetti F, Meazza C, Zeggini E, Lunt M, et al. Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum 2002; 46:2402-2409.
11. Donn R, Alourfi Z, Zeggini E, Lamb R, Jury F, Lunt M, et al. A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic. Arthritis Rheum 2004; 50:1604-1610.
12. Nohara H, Okayama N, Inoue N, Koike Y, Fujimura K, Suehiro Y, et al. Association of the - 173G/C polymorphism of the macrophage migration inhibitory factor gene with ulcerative colitis. J Gastroenterol 2004; 39:242-246.
13. Donn RP, Plant D, Jury F, Richards HL, Worthington J, Ray DW, Griffiths CE. Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. Dermatol J Invest 2004; 123:484-487.
14. Kumagi T, Akbar SMF, Horiike N, Onji M. Increased level of macrophage migration inhibitory factor (MIF) at the sera in alcoholic liver cirrhosis and their expression in liver tissues. Clin Biochem 2001; 34:189-193.
15. Akbar SMF, Abe M, Murakami H, Tanimoto K, Kumagi T, Yamashiata Y, et al. macrophage migration inhibitory factor in hepatocellular carcinoma and liver cirrhosis; relevance to pathogenesis. Cancer Lett 2001; 171:125-132.
16. ZhangW, Yue B, Wang GQ, Lu SL. Serum and ascites levels of macrophage migration inhibitory factor, TNF-alpha and IL-6 in patients with chronic virus hepatitis B and hepatitis cirrhosis. Hepatobiliary Pancreat Dis Int 2002; 1:577-580.
17. Zhang HY, Nanji AA, Lik JM, Huang XR, Lo CM, Chen YX, et al. Macrophage migration inhibitory factor expression correlates with inflammatory changes in human chronic hepatitis B infection. Liver Int 2005; 25:571-579.
18. Kimura K, Nagaki M, Nishihira J, Satake S, Kuwata K, Moriwaki H, et al. Role of macrophage migration inhibitory factor in hepatitis B virus specific cytotoxic-T-lymphocyte-induced liver injury. Clin Vaccine Immunol 2006; 13:415-419.
19. Kobayashi S, Nishihira J, Watanabe S, Todo S. Prevention of lethal acute hepatic failure by antimacrophage migration inhibitory factor antibody in mice treated with bacille Calmette-Guerin and lipopolysaccharide. Hepatology 1999; 29:1752-1759.
20. Ivaki T, Sugimura M, Nihihira J, Matsuura T, Kobayashi T, kanayama N. Recombinant adenovirus vector bearing antisense macrophage inhibitory factor cDNA prevents acute lipopolysaccharide-induced liver failure mice. Lab Invest 2003; 83:561-570.
21. Kleiner D, Brunt E, Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41:1313-1321.
22. Ludwig J, Viggiano TR, McGill DB. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55:434-438.
23. Marchesini G, Forlani G. NASH: from liver disease to metabolic disorders and back to clinical hepatology. Hepatology 2002; 35: 497-499.
24. Becker U, Deis A, Sorenson TL, Gronbaek M, Borch-Johnsen K, Mü ller CF, et al. Prediction of risk of liver disease by alcohol intake, sex and age: a prospective population study. Hepatology 1996; 23:1025-1029.
25. Diehl AM. Nonalcoholic steatohepatitis. Semin Liver Dis 1999; 19: 221-229.
26. Day C, James O. Steatohepatitis: a tale of two hits? Gastroenterology 1998; 114:842-845.
27. Poul Angulo MD. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346:1221-1231.
28. Harrison SA, Kadakia S, Long KA, Schenkers S. Nonalcoholic steatohepatitis: What we know in the new millennium. Am J Gastroenterol 2002; 97:2714-2724.
29. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122:1649-1657.
30. De Benedetti F, Meazza C, Vivarelli M, Rossi F, Pistorio A, Lamb R, et al. Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2003; 48:1398-1407.
31. Amoli MM, Donn RP, Thomson W, Hajeer AH, Garcia-Porrua C, Lueiro M, et al. Macrophage migration inhibitory factor gene polymorphism is associated with sarcoidosis in biopsy proven erythema nodosum. J Rheum 2002; 29:1671-1673.
32. Fingerle-Rowson G, Koch P, Bikoff R, Lin X, Metz CN, Dhabhar FS, et al. Regulation of macrophage migration inhibitory factor expression by glucocorticoids in vivo. Am J Pathol 2003; 162:47-56. (Pubitemid 36041989)
33. Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J. Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect 2002; 4:449-460.
34. Gregersen PK, Bucala R. Macrophage migration inhibitory factor, macrophage migration inhibitory factor alleles, and the genetics of inflammatory disorders: incorporating disease outcome into the definition of phenotype. Arthritis Rheum 2003; 48:1171-1176.
35. Arikan C, Berdeli A, Ozgenc F, Tumgor G, Yagci RV, Aydogdu S. Positive Association of Macrophage Migration Inhibitory Factor Gene-173G/C Polymorphism with Biliary Atresia. J Pediatr GastroenteroNutr 2005; 42:77-82.
36. Feldstein A, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ. Hepatocyte Apoptosis and Fas Expression Are Prominent Features of Human Nonalcoholic Steatohepatitis. Gastroenterology 2003; 125:437-443.
37. Canbay A, Higuchi H, Bronk SF, Taniai M, Sebo TJ, Gores GJ. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 2002; 123:1323-1330.
38. Canbay A, Tamir P, Torok NJ, Higuchi H, Friedman SL, Gores GJ. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003; 83:655-663.